Amgen Inc Stock Price, News & Analysis

Amgen (NASDAQ:AMGN) reported strong Q2 2025 financial results with total revenues increasing 9% to $9.2 billion. Product sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. GAAP EPS increased 92% to $2.65, while non-GAAP EPS rose 21% to $6.02.

Key highlights include fifteen products achieving double-digit sales growth, notably Repatha (+31%), EVENITY (+32%), UPLIZNA (+91%), and TEZSPIRE (+46%). The company generated $1.9 billion in free cash flow and maintained its 2025 revenue guidance of $35.0-36.0 billion.

However, some established products faced challenges, with Enbrel sales declining 34% and Prolia/XGEVA expecting sales erosion due to biosimilar competition in H2 2025.

Amgen (NASDAQ:AMGN) has announced its quarterly dividend payment for Q3 2025. The company's Board of Directors has declared a dividend of $2.38 per share. The dividend will be distributed on September 12, 2025, to stockholders who are on record as of the market close on August 22, 2025.

Amgen (NASDAQ:AMGN) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after U.S. market close. The company will host a conference call at 4:30 p.m. ET featuring CEO Robert A. Bradway and senior management.

The event will be accessible via webcast on www.amgen.com under the Investors section, with replay available for at least 90 days following the presentation.

Amgen (NASDAQ:AMGN) announced positive topline results from its Phase 3 FORTITUDE-101 clinical trial for bemarituzumab in gastric cancer treatment. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in overall survival (OS) when combining bemarituzumab with chemotherapy compared to placebo plus chemotherapy.

The study focused on patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and non-HER2 positive status. This breakthrough is particularly significant given that gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths annually.

The most common treatment-emergent adverse events included reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye. Notably, ocular events occurred with greater frequency and severity in the bemarituzumab arm compared to the Phase 2 experience. A separate Phase 3 study combining bemarituzumab with chemotherapy and nivolumab is ongoing, with results expected in H2 2025.

Amgen announced positive Phase 2 results for MariTide (maridebart cafraglutide), a monthly obesity treatment. The drug achieved ~20% average weight loss in non-diabetic obese patients and ~17% in those with Type 2 diabetes after 52 weeks, significantly outperforming placebo. Notably, weight loss hadn't plateaued at study end, suggesting potential for further reduction. The drug demonstrated significant cardiometabolic improvements and HbA1c reduction up to 2.2% in diabetic patients. Safety profile aligned with GLP-1 class, with mainly mild to moderate gastrointestinal side effects. Lower starting doses improved tolerability without compromising efficacy. Amgen is advancing to Phase 3 MARITIME trials for chronic weight management, with additional studies planned for cardiovascular disease, heart failure, and sleep apnea in 2025.

Amgen will present key data for MariTide, its investigational monthly obesity and Type 2 diabetes treatment, at the American Diabetes Association's 85th Scientific Sessions. The presentation will showcase 52-week efficacy and safety data from Phase 2 studies, showing significant weight loss without plateauing in patients with and without Type 2 diabetes. MariTide represents a breakthrough as the first monthly or less frequently dosed peptide-antibody conjugate for obesity treatment. The company will also present new Repatha data regarding lipid-lowering therapy benefits in Type 1 diabetes patients. Amgen will host an investor webcast on June 23, 2025, at 4:30 p.m. CDT to discuss the MariTide program. The scientific sessions will feature additional presentations on cardiovascular efficacy and lipid-lowering therapy patterns from the FOURIER and VESALIUS-REAL studies.

Amgen (AMGN) has launched 'The Making of a Heart Attack', a documentary featuring football legend Barry Sanders, who reveals his personal heart attack experience from Father's Day 2024. The documentary aims to raise awareness about high LDL (bad) cholesterol as a major risk factor for cardiovascular events. Sanders joins other cardiovascular disease survivors and medical experts to educate viewers about the dangers of high LDL-C, noting that over 40% of U.S. adults with high LDL-C are unaware of their condition. The documentary is part of Amgen's initiative to reduce heart attacks and strokes in the U.S. by half by 2030. The film will premiere on A&E on June 14, 2025, and will be available online at AttackHeartDisease.com/Documentary from June 16, 2025.

Amgen (NASDAQ: AMGN) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 9:20 a.m. PT. The company will be represented by Peter Griffith, EVP and CFO, and Jay Bradner, EVP of Research and Development. The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast will remain available for replay for at least 90 days following the event, along with other selected management presentations from investor and medical conferences.

BetterInvesting Magazine has announced The Walt Disney Co. (NYSE: DIS) as its "Stock to Study" for the August 2025 issue, replacing the previously selected Stride Inc. The decision comes as investors question whether Disney's stock is overvalued or presents a buying opportunity. The magazine will provide comprehensive fundamental data analysis, including sales, earnings, pre-tax profit, and return on equity metrics through the National Association of Investors Corp. The August 2025 issue will also feature a fundamental review of Amgen Inc. (NASDAQ: AMGN), which the Editorial Advisory and Securities Review Committee considers potentially undervalued. The committee, comprising six CFA charterholders and chaired by editor Doron P. Levin, emphasizes that these securities are presented for educational purposes only and should not be considered as endorsed investment recommendations.